EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Argenx struck a deal to use Halozyme’s delivery technology to develop subcutaneous formulations of its current and future drug candidates. The biotech paid $30 million (€26 million) upfront to land the deal. Statement 

> Newron Pharmaceuticals completed enrollment in its pivotal Rett syndrome trial. The milestone sets Newron up to deliver top-line results before the end of the year. Release 

> Sotio named Harald Fricke as its CMO. Fricke last worked at Apogenix, a company he co-founded in 2006. Statement 

CONFERENCE

AI Innovations for Life Science and Healthcare Summit East

Join the expert speaking faculty of over 30 life science, healthcare, and tech professionals on June 13–14, 2019, in Philadelphia, as we elevate clinical trial operations, healthcare outcomes, and supply chain implementation through AI. Use Discount Code 796819FIERCE to save 15% off the standard registration rate.

> Audion Therapeutics posted phase 1 data on its notch inhibitor in patients with mild to moderate sensorineural hearing loss. A phase 2 trial of the drug started last month. Release  

> BioLineRx priced $15.4 million worth of shares and warrants. Statement

> UniQure dosed the first patient in its pivotal hemophilia B trial. The gene therapy trial is expected to be fully enrolled by the end of the year. Release 

Suggested Articles

Aduro Biotech has a new chief medical officer: Dimitry Nuyten, M.D., Ph.D.

USC researchers believe they have early evidence that a CAR-T designed to sidestep cytokine release syndrome may be safe enough for outpatient use.

Tonix Pharmaceuticals has lost a U.S. Army agreement to develop TNX-102 SL in military-related post-traumatic stress disorder.